MedTrace Logo

ADME Study of [14C]- Larotinib in Healthy Male Subjects

NCT05059743 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-03-21

No results posted yet for this study

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]-Larotinib（Z650）in healthy male subjects.

Conditions

  • Healthy Adult Male Volunteers

Interventions

DRUG

[14C]-Larotinib

Patients will receive single dose of orally \[14C\]-Larotinib on Day 1.

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • liyan Miao, MD · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-20
Primary Completion
2022-01-10
Completion
2022-01-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059743 on ClinicalTrials.gov